Spanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer.
Dr Meya brings over 30 years of research and development experience to the firm, with a background as a neurologist and psychiatrist.
He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders.
Prior to this, Dr Meya was head of phase I and II clinical studies in neurodegenerative disorders at Synosia Therapeutics, and served as head of research portfolio management and clinical research and licensing liaison manager in CNS at Roche.
He also has leadership experience working at Novartis in CNS clinical development, at Knoll as head of clinical development, and as a medical advisor and the head of clinical psychiatry at Schering.
Marc Martinell, chief executive officer of Minoryx Therapeutics, said: “We are delighted to welcome Dr Meya as our chief medical officer.
“Hi wealth of expertise in CNS-related research will help us significantly in moving forward the clinical development of our lead candidate MIN-102. He will also support the further development of our pipeline in orphan diseases.”